Latest News

AMA survey: 93% of providers say prior authorizations delay care with 91% reporting negative clinical impact.

CANN announces 2022 organizational changes including rebranding and launching the 340B Action Center.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

New CANN leadership reflects on mentorship and maintaining advocacy legacy following Bill Arnold's passing.

Final installment addressing 340B reform needs: transparency, accountability, and contract pharmacy concerns.

Analyzes the role of contract pharmacies and intermediaries in 340B drug distribution and patient access.

Examines how 340B program expansion correlates with declining hospital charity care for vulnerable patients.

Explores accountability mechanisms in the 340B program and oversight requirements for patient protection.

Explains why transparency in 340B operations is critical for program integrity and patient access.

Introduces the 340B Drug Discount Program: its history, purpose, and significance for medication access.

Overview of the 340B Drug Discount Program for patient advocates covering program history and key policy issues.

Calls for restoring Obama-era guidance defining 340B patient protections and enforcement mechanisms.

Examines CMS's rebate rule on copay accumulator programs that block patient assistance from counting toward deductibles.

Broken advocacy pipeline lacks investment in leadership development, compensation, and mentorship.

Merck-Gilead partnership on long-acting injectables Islatravir and Lenacapavir for HIV treatment.

CANN outlines advocacy priorities for the Biden era, from 340B reform and drug pricing to HIV criminalization and health equity.